Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000632636 | SCV000753821 | likely benign | Neurofibromatosis, type 2 | 2024-11-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001025713 | SCV001187957 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-25 | criteria provided, single submitter | clinical testing | The p.K228R variant (also known as c.683A>G), located in coding exon 8 of the NF2 gene, results from an A to G substitution at nucleotide position 683. The lysine at codon 228 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000632636 | SCV002044857 | uncertain significance | Neurofibromatosis, type 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003459508 | SCV004199032 | uncertain significance | Familial meningioma | 2023-10-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004760664 | SCV005370120 | uncertain significance | not provided | 2023-05-30 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 11756419, 16324214) |